Merck said Q4 2025 sales were $16,400 million, a 5% increase, and full-year sales were $65,011 million, a 1% increase. Full-year GAAP EPS was $7.28 and non-GAAP EPS was $8.98.

1. 01

   Merck said Q4 2025 sales were $16,400 million, a 5% increase, and full-year sales were $65,011 million, a 1% increase. Full-year GAAP EPS was $7.28 and non-GAAP EPS was $8.98.

2. 02

   The company said 2025 KEYTRUDA/KEYTRUDA QLEX sales were $31,680 million, a 7% increase, and GARDASIL/GARDASIL 9 sales were $5,233 million, a 39% decline.

3. 03

   Merck said 2025 WINREVAIR sales were $1,443 million, CAPVAXIVE sales were $759 million and Animal Health sales were $6,354 million, a 8% increase.

4. 04

   The company said it anticipates 2026 sales to be between $65.5 billion and $67.0 billion and non-GAAP EPS to be between $5.00 and $5.15. The EPS outlook includes a one-time charge of approximately $3.65 per share related to the acquisition of Cidara.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.